CO2021014253A2 - Formulación de tableta vaginal - Google Patents

Formulación de tableta vaginal

Info

Publication number
CO2021014253A2
CO2021014253A2 CONC2021/0014253A CO2021014253A CO2021014253A2 CO 2021014253 A2 CO2021014253 A2 CO 2021014253A2 CO 2021014253 A CO2021014253 A CO 2021014253A CO 2021014253 A2 CO2021014253 A2 CO 2021014253A2
Authority
CO
Colombia
Prior art keywords
tablet formulation
vaginal tablet
vaginal
glucono
lactone
Prior art date
Application number
CONC2021/0014253A
Other languages
English (en)
Inventor
Ulf Ellervik
Sophie Manner
Olov Sterner
Helena Strevens
Nils-Olof Lindberg
Annette Säfholm
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of CO2021014253A2 publication Critical patent/CO2021014253A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende glucono-δ-lactona, que es adecuada para uso en el tratamiento de infecciones microbianas vaginales.
CONC2021/0014253A 2019-04-05 2021-10-25 Formulación de tableta vaginal CO2021014253A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05
PCT/EP2020/059582 WO2020201515A1 (en) 2019-04-05 2020-04-03 Vaginal tablet formulation

Publications (1)

Publication Number Publication Date
CO2021014253A2 true CO2021014253A2 (es) 2021-11-19

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014253A CO2021014253A2 (es) 2019-04-05 2021-10-25 Formulación de tableta vaginal

Country Status (24)

Country Link
US (1) US20220193031A1 (es)
EP (1) EP3976000B1 (es)
JP (1) JP2022537478A (es)
KR (1) KR20210148195A (es)
CN (1) CN113660928B (es)
AR (1) AR118580A1 (es)
AU (1) AU2020252268A1 (es)
BR (1) BR112021019999A2 (es)
CA (1) CA3134086A1 (es)
CL (1) CL2021002430A1 (es)
CO (1) CO2021014253A2 (es)
EA (1) EA202192716A1 (es)
ES (1) ES2961736T3 (es)
HU (1) HUE062772T2 (es)
IL (1) IL286942A (es)
MA (1) MA56011A (es)
MX (1) MX2021012146A (es)
PE (1) PE20220381A1 (es)
PL (1) PL3976000T3 (es)
SG (1) SG11202110236QA (es)
TW (1) TW202103693A (es)
UA (1) UA127823C2 (es)
WO (1) WO2020201515A1 (es)
ZA (1) ZA202106877B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69802260T2 (de) * 1998-04-30 2002-07-04 Vesely Renata Maria Cavaliere Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2017174731A1 (en) * 2016-04-06 2017-10-12 Gedea Biotech Ab Glucono delta-lactone for treatment of vaginal fungal infections
MX2020003660A (es) 2017-10-06 2020-08-03 Gedea Biotech Ab Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.

Also Published As

Publication number Publication date
SG11202110236QA (en) 2021-10-28
WO2020201515A1 (en) 2020-10-08
JP2022537478A (ja) 2022-08-26
CN113660928A (zh) 2021-11-16
PL3976000T3 (pl) 2023-12-04
ZA202106877B (en) 2023-03-29
AR118580A1 (es) 2021-10-20
EA202192716A1 (ru) 2022-01-17
IL286942A (en) 2021-12-01
HUE062772T2 (hu) 2023-12-28
BR112021019999A2 (pt) 2021-12-07
CA3134086A1 (en) 2020-10-08
EP3976000A1 (en) 2022-04-06
TW202103693A (zh) 2021-02-01
MA56011A (fr) 2022-04-06
CL2021002430A1 (es) 2022-07-01
EP3976000C0 (en) 2023-08-02
AU2020252268A1 (en) 2021-10-21
ES2961736T3 (es) 2024-03-13
MX2021012146A (es) 2021-12-10
US20220193031A1 (en) 2022-06-23
UA127823C2 (uk) 2024-01-10
PE20220381A1 (es) 2022-03-18
EP3976000B1 (en) 2023-08-02
KR20210148195A (ko) 2021-12-07
CN113660928B (zh) 2024-04-05

Similar Documents

Publication Publication Date Title
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
NI201500048A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2020001242A2 (es) Dihidrooxadiazinonas
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
NI201900063A (es) Amidas aromáticas de ácido carboxílico
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.
CO2021014253A2 (es) Formulación de tableta vaginal
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CR20190466A (es) Tratamiento de una infección vaginal bacteriana
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
MX2020004105A (es) Formulacion farmaceutica.
BR112021013607A2 (pt) Compostos bicíclico contendo nitrogênio